Coverage / LON:HCM / Trade Card

LON:HCM

HUTCHMED (China) Ltd

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-13 Market data 2 days old 222.50p Healthcare - Drug Manufacturers - Specialty & GenericAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
222.50p
Buy <=wait / entry
180.00p
Trim >=take some off
240.00p
Thesis breakA confirmed US launch setback for FRUZAQLA, a dilutive equity raise to extend th...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • China product sales growth over 40% for ELUNATE and SULANDA in H1 2026
  • FRUZAQLA ex-US sales expansion with approvals or launches in 41 countries
  • New drug approvals for fruquintinib (RCC) and savolitinib (GC)
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n